Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perhexiline for symptomatic hypertrophic cardiomyopathy
ACTRN12620000785909Phase 2Not yet recruiting
- Sponsor
- Flinders Medical Centre
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hypertrophic cardiomyopathy (HCM) comparing Perhexiline with Placebo (2 arms). Primary endpoint: Change in left ventricular hypertrophy. Planned start Sep 2020; status: not yet recruiting.
02
Drugs
perhexiline
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on ACTRN12620000785909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000785909.